Figure 4.

DRrejTs eliminate re-inoculated ENKL

(A) LMP2-rejT-treated or DRrejT-treated ENKL-inoculated mice were re-inoculated with ENKL cells. Bioluminescence imaging of re-inoculated mice: LMP2-rejT-treated mice (n = 2) or DRrejT-treated mice (n = 3). ENKL (1 × 10⁵ cells) were injected intraperitoneally into survivors of a previous experiment, without additional rejTs. (B) Flow cytometric analysis of tetramer⁺/CD3⁺ population from peripheral blood of LMP2-rejT- or DRrejT-treated ENKL re-inoculated mice. The plots represent two independent experiments. (C) Flow cytometric analysis of memory phenotype (CD45RA and CD62L population) from peripheral blood of LMP2-rejT- or DRrejT-treated ENKL re-inoculated mice. The plots represent two independent experiments. (D) LMP2-rejTs (no iC9) and DRrejTs (with iC9) were treated with CID (80 nM) and apoptosis was measured 24 h later by flow cytometry for annexin V/7-AAD positivity. Data represent three independent triplicate experiments. Cells were counted using counting beads on flow cytometry. Graph summarizes the results of total apoptotic cell number. Error bars represent ± SD. ∗∗∗∗p < 0.0001 by two-way ANOVA. ns, not significant.